MacroGenics Raises $25M in Series D-2 Financing. - 09/25/2008

MacroGenics Acquires Raven Biotechnologies - 07/17/2008

Macrogenics Appoints New Chief Commercial Officer and Chief Financial Officer - 05/06/2008

Lilly and MacroGenics Announce Licensing and Collaboration Agreement - 10/18/2007

Jeffrey H. Buchalter Joins Macrogenics Board of Directors as Chairman - 09/26/2007

Macrogenics Begins Global Phase 2/3 Protégé Study In Recent-onset Type 1 Diabetes Mellitus - 08/02/2007

MacroGenics IND for West Nile Virus Monoclonal Antibody IS ACTIVE Phase 1 Clinical Trial to Commence in 2007 - 07/09/2007

MacroGenics and JDRF Form Partnership to Support Pivotal Phase II/III Clinical Trial of Anti-CD3 Monoclonal Antibody for Children and Adults with Recent-Onset Type 1 Diabetes - 01/03/2007

MacroGenics Elects Industry Leader, Dr. John Maraganore, to Board of Directors - 10/16/2006

MacroGenics Receives Orphan Drug Designation from FDA for Monoclonal Antibody to Treat Type 1 Diabetes - 10/10/2006

MacroGenics Novel Monoclonal Antibody Shows Potent Anti-tumor Activity against B-Cell Lymphoma in Preclinical Studies - 10/05/2006

MacroGenics receives multiple government awards totaling more than $62 million to advance infectious disease programs - 10/02/2006

MacroGenics Raises $45M in Series C Financing - Company to Advance Monoclonal Antibody Clinical Programs - 05/17/2006

MacroGenics Announces Grand Opening of New cGMP Manufacturing  Facility in Montgomery County, Maryland Biotech Corridor - 10/19/2005

Promising Treatment for Juvenile Diabetes Advances with Agreement Signed by MacroGenics and Tolerance Therapeutics - 07/18/2005

MacroGenics Builds Senior Management Team by Adding CFO and VP of Clinical Research - 06/17/2005

MacroGenics Inc. To License Novel Monoclonal Antibody Target From OriGene Technologies, Inc. - 10/19/2004

MacroGenics Completes Series B Financing - 10/15/2004

Neose Technologies and MacroGenics Sign Research Collaboration and License Agreement - 04/26/2004

Genzyme, MacroGenics Announce Joint Effort to Develop New Therapies for Immune-Mediated Diseases - 10/29/2003

HHS Names UTMB, Seven Others as New Regional Centers To Focus on Biodefense Research - 09/04/2003

MacroGenics Acquires Eliance, Inc., and Establishes Partnership in Immunotherapeutics with UT Southwestern. - 06/07/2002

MacroGenics Announces Senior Appointments - 04/01/2002

MacroGenics Raises $13.5 Million and Appoints President and CEO - 09/25/2001